New pharmacological tools for obesity

Journal of Endocrinological Investigation

Volumn 25, Issue 10, 2002, Pages 905-914

  Nisoli, Enzo ^a,b   Carruba, M O ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b ISTITUTO AUXOLOGICO ITALIANO   (Italy)

Author keywords

Anti obesity drugs; Metabolic fitness; Obesity; Obesity related disorders

Indexed keywords

6 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL] 1,4 BENZODIOXAN 2 CARBOXYLIC ACID; ANOREXIGENIC AGENT; ANTIOBESITY AGENT; ATL 962; AZ 40140; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; CANNABINOID; CANNABINOID 1 RECEPTOR; ENDOCANNABINOID; FATTY ACID SYNTHASE INHIBITOR; GHRELIN; GHRELIN RECEPTOR; GI 181771; INSULIN AGONIST; LEPTIN; LEPTIN RECEPTOR; LY 377604; MELANIN CONCENTRATING HORMONE; MELANIN CONCENTRATING HORMONE RECEPTOR; MELANOCORTIN RECEPTOR; MLN 4760; NEUROPEPTIDE; NEUROPEPTIDE RECEPTOR; NEUROPEPTIDE Y RECEPTOR ANTAGONIST; P 57; PEPTIDE YY 3-36; PROOPIOMELANOCORTIN; RECOMBINANT CILIARY NEUROTROPHIC FACTOR; RECOMBINANT LEPTIN; RIMONABANT; SB 418790; SEROTONIN AGONIST; SIBUTRAMINE; SNAP 7941; TETRAHYDROLIPSTATIN; TOPIRAMATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; CYCLOBUTANE DERIVATIVE; LACTONE;

ADIPOSE TISSUE; BODY WEIGHT; CALORIC INTAKE; CANCER; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DEFECATION DISORDER; DIABETES MELLITUS; DRUG ABSORPTION; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; ENERGY EXPENDITURE; ENVIRONMENTAL FACTOR; EPIDEMIC; FECES INCONTINENCE; FLATULENCE; GLOBAL CHANGE; HEART ARRHYTHMIA; HIGH RISK PATIENT; HUMAN; HYPERLIPIDEMIA; HYPERPHAGIA; HYPERTENSION; INDUSTRIALIZATION; LEAN BODY WEIGHT; LUNG DISEASE; MULTIFACTORIAL INHERITANCE; NONHUMAN; NUTRIENT UPTAKE; OBESITY; OPTIMAL DRUG DOSE; OSTEOARTHRITIS; PATHOPHYSIOLOGY; PRESCRIPTION; REVIEW; SIDE EFFECT; SLEEP APNEA SYNDROME; STEATORRHEA; STROKE; TACHYCARDIA; ANIMAL; DRUG INDUSTRY;

ANIMALS; ANTI-OBESITY AGENTS; APPETITE DEPRESSANTS; CYCLOBUTANES; DRUG INDUSTRY; HUMANS; LACTONES; OBESITY;

EID: 0036861128     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03344055     Document Type: Review

References (84)

1. World Health Organization. Obesity: Preventing and Managing the Global Epidemic. World Health Organization, Geneva, 1998.
2. Pi-Sunyer F.X. Medical hazards of obesity. Ann. Int. Med. 1993, 119: 655-660.
3. Wickelgren I. Obesity: How big a problem? Science 1998, 280: 1364-1357.
4. Williamson D.F., Pamuk E., Thun M., Flanders D., Byers T., Heath C. Prospective study of intentional weight loss and mortality in never-smoking US white women aged 40-64 years. Am. J. Epid. 1995, 141: 1128-1141.
5. Hill J.O., Peters J.C. Environmental contributions to the obesity epidemic. Science 1998, 280: 1371-1374.
6. Woods S.C., Seeley R.J., Porte D. Jr., Schwartz M.W. Signals that regulate food intake and energy homeostasis. Science 1998, 280: 1378-1383.
7. Blackburn L., Miller D., Chan S. Pharmaceutical treatment of obesity. Nurs. Clin. North Am. 1997, 32: 831-848.
8. American Association of Clinical Endocrinologists (AACE)/American College of Endocrinology (ACE). Obesity statement. Endocr. Pract. 1997, 3: 165-208.
9. Shape Up America!, the American Obesity Association. Guidance for Treatment of Adult Obesity. American Obesity Association, Chicago, 1996.
10. National Task Force on the Prevention and Treatment of Obesity. Long-term pharmacotherapy in the management of obesity. JAMA 1996, 276: 1907-1915.
11. Nisoli E., Carruba M.O. An assessment of the safety and efficacy of sibutramine, an anti-obesity drug with a novel mechanism of action. Obes. Rev. 2000, 1: 127-139.
12. James W.P., Astrup A., Finer N. et al. Effect of sibutramine on weight maintenance after weight loss: A randomised trial. Lancet 2000, 356: 2119-2125.
13. Apfelbaum M., Vague P., Ziegler O., Hanotin C., Thomas F., Leutenegger E. Long-term maintenance of weight loss after a very-low-calorie diet: A randomized blinded trial of the efficacy and tolerability of sibutramine. Am. J. Med. 1999, 106: 179-184.
14. Heck A.M., Yanovski J.A., Calis K.A. Orlistat, a new lipase inhibitor for the management of obesity. Pharmacotherapy 2000, 20: 270-279.
15. Yanovski S.Z., Yanovski J.A. Obesity. N. Engl. J. Med. 2002, 346: 591-602.
16. Hollander P.A., Elbein S.C., Hirsch I.B. et al. Role of orlistat in the treatment of obese patients with type 2 diabetes: A 1-year randomized double-blind study. Diabetes Care 1998, 21: 1288-1294.
17. Hauptman J., Lucas C., Boldrin M.N., Collins H., Segal K.R. Orlistat in the long-term treatment of obesity in primary care settings. Arch. Fam. Med. 2000, 9: 160-167.
18. Farrigan C., Pang K. Obesity market overview. Nat. Rev. Drug Discov. 2002, 1 (4): 257-8.
19. Montague C.T., Faroqui I.S., Whitehead J.P. et al. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 1997, 387: 903-908.
20. Strobel A., Issad T., Camoin L., Ozata M., Strosberg A.D. A leptin missense mutation associated with hypogonadism and morbid obesity. Nat. Genet. 1998, 18: 213-215.
21. Zhang Y., Proenca R., Maffeis M. et al. Positional cloning of the mouse obese gene and its human homologue. Nature 1994, 372: 425-432.
22. Farooqi I.S., Jebb S.A., Longmack G. et al. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N. Engl. J. Med. 1999, 341: 879-884.
23. Halaas J.L., Gajiwaka K.S., Maffei M. et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science 1995, 269: 543-546.
24. Heymsfield S.B. Recombinant leptin for weight loss in obese and lean adults: A randomized, controlled, dose-escalation trial. JAMA 1999, 1568-1575.
25. Caro J.F., Kolaczynski J.W., Nyce N.R. et al. Decreased cerebrospinal-fluid/serum leptin ratio in obesity: A possible mechanism for leptin resistance. Lancet 1996, 348: 159-161.
26. Farooqi I.S., Keogh J.M., Kamath S. et al. Metabolism: Partial leptin deficiency and human adiposity. Nature 2001, 414: 34-35.
27. Sleeman M.W., Anderson K.D., Lambert P.D., Yancopoulos G.D., Wiegand S.J. The ciliary neurotrophic factor and its receptor, CNTFR. Pharm. Acta Helv. 2000, 74: 265-272.
28. Lambert P.D., Anderson K.D., Steeman M.W. et al. Ciliary neurotrophic factor activates leptin-like pathways and reduces body fat, without cachexia or rebound weight gain, even in leptin-resistant obesity. Proc. Natl. Acad. Sci. USA 2001, 98: 4652-4657.
29. Cone R.D. The central melanocortin system and energy homeostasis. Trends Endocrinol. Metab. 1999, 10: 211-216.
30. Mountjoy K., Mortrud M., Low M., Simerly R., Cone R. Localization of the melanocortin-4 receptor (MC4-R) in neuroendocrine and autonomic control circuits in the brain. Mol. Endocrinol. 1994, 8: 1298-1308.
31. Fan W., Boston B., Kesterson R., Hruby V., Cone R. Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature 1997, 385: 165-168.
32. Huszar D., Lynch C.A., Fairchild-Huntress V. et al. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 1997, 88: 131-141.
33. Vaisse C., Clement K., Guy-Grand B., Froguel P. A frameshift mutation in human MC4R is associated with a dominant form of obesity. Nat. Genet. 1998, 20: 113-114.
34. Shutter J., Graham M., Kinsey A. et al. Hypothalamic expression of ART, a novel gene related to agouti, is up-regulated in obese and diabetic mutant mice. Genes Dev. 1997, 11: 593-602.
35. Ollmann M., Wilson B.D., Yang Y.K. et al. Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein. Science 1997, 278: 135-138.
36. Schwartz M.W., Woods S.C., Porte D Jr., Seeley R.J., Baskin D.G. Central nervous system control of food intake. Nature 2000, 404: 661-671.
37. Hagan M.M., Rushing P.A., Pritchard L.M. et al. Long-term orexigenic effects of AgRP-(83-132) involve mechanisms other than melanocortin receptor blockade. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2000, 279: R47-R52.
38. Obici S., Feng Z., Tan J., Liu L., Karkanias G., Rossetti L. Central melanocortin receptors regulate insulin action. J. Clin. Invest. 2001, 108: 1079-85.
39. Stanley B.G., Leibowitz S.F. Neuropeptide Y: Stimulation of feeding and drinking by injection into the paraventricular nucleus. Life Sci. 1984, 35: 2635-2642.
40. Akabayashi A., Wahlestedt C., Alexander J.T., Leibowitz S.F. Specific inhibition of endogenous neuropeptide Y synthesis in arcuate nucleus by antisense oligonucleotides suppresses feeding behavior and insulin secretion. Brain Res. Mol. Brain Res. 1994, 21: 55-61.
41. Shibasaki T., Oda T., Imaki T., Ling N., Demura H. Injection of anti-neuropeptide Y-globulin into the hypothalamic paraventricular nucleus decreases food intake in rats. Brain Res. 1993, 601: 313-316.
42. Kushi A., Sasai H., Koizumi H. et al. Obesity and mild hyperinsulinemia found in neuropeptide Y Y1 receptor-deficient mice. Proc. Natl. Acad. Sci. USA 1998, 95: 15659-15664.
43. Pedrazzini T., Seydoux J., Kunster P. et al. Cardiovascular response, feeding behavior and locomotor activity in mice lacking the NPY Y1 receptor. Nat. Med. 1998; 4: 722-726.
44. Naveilhan P., Hassani H., Canals J.M. et al. Normal feeding behavior, body weight and leptin response require the neuropeptide Y Y2 receptor. Nat. Med. 1999, 5: 1188-1193.
45. Marsh D.J., Hollopeter G., Kafer K.E., Palmiter R.D. Role of the Y5 neuropeptide Y receptor in feeding and obesity. Nat. Med. 1998, 4: 718-721.
46. Kristensen P., Judge M.E., Thim L. et al. Hypothalamic CART is a new anorectic peptide regulated by leptin. Nature 1998, 393: 72-76.
47. Asnicar M.A., Smith D.P., Yang D.D. et al. Absence of cocaine- and amphetamine-regulated transcript results in obesity in mice fed a high caloric diet. Endocrinology 2001, 142: 4394-4400.
48. Aja S., Sahandy S., Ladenheim E.E., Schwartz G.J., Moran T.H. Intracerebroventricular CART peptide reduces food intake and alters motor behavior at a hindbrain site. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2001, 281: R1862-R1867.
49. Spina M., Merlo-Pich E., Chan R.K. Appetite-suppressing effects of urocortin, a CRF-related neuropeptide. Science 1996, 273: 1561-1564.
50. Coste S.C., Kesterson R.A., Heldwein K.A. et al. Abnormal adaptations to stress and impaired cardiovascular function in mice lacking corticotropin-releasing hormone receptor-2. Nat. Genet. 2000, 24: 403-409.
51. Bradbury M.J., McBurnie M.I., Denton D.A., Lee K.F., Vale W.W. Modulation of urocortin-induced hypophagia and weight loss by corticotropin-releasing factor receptor 1 deficiency in mice. Endocrinology 2000, 141: 2715-2724.
52. Van Dijk G., Thiele T.E. Glucagon-like peptide-1 (7-36) amide: A central regulator of satiety and interoceptive stress. Neuropeptides 1999, 33: 406-414.
53. Bray G.A. Afferent signals regulating food intake. Proc. Nutr. Soc. 2000, 59: 373-384.
54. Scrocchi L.A., Brown T.J., McClusky N. et al. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat. Med. 1996, 2: 1254-1258.
55. Wallenius V., Wallenius K., Ahren B. et al. Interleukin-6-deficient mice develop mature-onset obesity. Nat. Med. 2002, 8: 75-79.
56. Kernie S.G., Liebl D.J., Parada L.F. BDNF regulates eating behavior and locomotor activity in mice. EMBO J. 2000, 19: 1290-1300.
57. Langmead C.J., Szekeres P.G., Chambers J.K. et al. Characterization of the binding of [(125)I]-human prolactin releasing peptide (PrRP) to GPR10, a novel G protein coupled receptor. Br. J. Pharmacol. 2000, 131: 683-688.
58. Howard A.D., Wang R., Pong S.S. et al. Identification of receptors for neuromedin U and its role in feeding. Nature 2000, 406: 70-74.
59. Bittencourt J.C., Presse F., Arias C. et al. The melanin-concentrating hormone system of the rat brain: An immuno- and hybridization histochemical characterization. J. Comp. Neurol. 1992, 319: 218-245.
60. Qu D., Ludwig D.S., Gammeltoft S. et al. A role for melanin-concentrating hormone in the central regulation of feeding behaviour. Nature 1996, 380: 243-247.
61. Borosky B., Durkin M.M., Ogozalek K. et al. Antidepressant, anxiolytic and anorectic effects of a melanin-concentrating hormone-1 receptor antagonist. Nat. Med. 2002, 8: 825-830.
62. Gonzalez S., Manzanares J., Berrendero F. et al. Identification of endocannabinoids and cannabinoid CB(1) receptor mRNA in the pituitary gland. Neuroendocrinology 1999, 70: 137-145.
63. Mechoulam R., Hanus L., Fride E. Towards cannabinoid drugs - Revisited. Prog. Med. Chem. 1998, 35: 199-243.
64. Di Marzo V., Goparaju S.K., Wang L. et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001, 410: 822-825.
65. Kojima M., Hasoda H., Date Y., Nakazato M., Matsuo H., Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999, 402: 656-660.
66. Nakazato M., Murakami H., Date Y. et al. A role for ghrelin in the central regulation of feeding. Nature 2001, 409: 194-218.
67. Tschop M., Smiley D.L., Heiman M.L. Ghrelin induces adiposity in rodents. Nature 2000, 407: 908-913.
68. Pedersen-Bjergaard U., Host U., Kelbaek H. et al. Influence of meal composition on postprandial peripheral plasma concentrations of vasoactive peptides in man. Scand. J. Clin. Lab. Invest. 1996, 56: 497-503.
69. (3-36) physiologically inhibits food intake. Nature 2002, 418: 650-654.
70. Cowley M.A., Smart J.L., Rubinstein M. et al. Leptin activates the anorexigenic POMC neurons through a neural network in the arcuate nucleus. Nature 2001, 411: 480-484.
71. Loftus T.M.,Jaworsky D.E., Frehywot G.L. et al. Reduced food intake and body weight in mice treated with fatty acid synthase inhibitors. Science 2000, 288: 2379-2381.
72. Moule S.K., Edgell N.J., Welsh G.I. et al. Multiple signalling pathways involved in the stimulation of fatty acid and glycogen synthesis by insulin in rat epididymal fat cells. Biochem. J. 1995, 311: 595-601.
73. Niswender K.D., Marton G.J., Stearns W.H., Rhodes C.J., Myers M.G. Jr., Sichwartz M.W. Intracellular signalling. Key enzyme in leptin-induced anorexia. Nature 2001, 413: 794-795.
74. Shepherd P.R., Withers D.J., Siddle K. Phosphoinositide 3-kinase: The key switch mechanism in insulin signalling. Biochem. J. 1998, 333: 471-490.
75. Yang X.J., Kow L.M., Funabashi T., Mobbs C.V. Hypothalamic glucose sensor: Similarities to and differences from pancreatic -cell mechanisms. Diabetes 1999, 48: 1672-1763.
76. Obici S., Feng Z., Margan K., Stein D., Karkanias G., Rossetti L. Central administration of oleic acid inhibits glucose production and food intake. Diabetes 2002, 51: 271-275.
77. Shimokawa T., Kumar M.V., Lane M.D. Effect of a fatty acid synthase inhibitor on food intake and expression of hypothalamic neuropeptides. Proc. Natl. Acad. Sci. USA 2002, 99: 66-71.
78. Bruning J.C., Gantam D., Burks D.J. et al. Role of brain insulin receptor in control of body weight and reproduction. Science 2000, 289: 2122-2125.
79. DeFronzo R. Pharmacological therapy for type 2 diabetes. Ann. Intern. Med. 1999, 17: 281-303.
80. Air E.L., Strowski M.Z., Benoit S.C. et al. Small molecule insulin mimetics reduce food intake and body weight and prevent development of obesity. Nat. Med. 2002, 8 (2): 179-183.
81. Zhang B., Salituro G., Szalkowski D. et al. Discovery of a small molecule insulin mimetic with antidiabetic activity in mice. Science 1999, 284: 974-977.
82. Qureshi S.A., Ding V., Li Z. et al. Activation of insulin signal transduction pathway and anti-diabetic activity of small molecule insulin receptor activators. J. Biol. Chem. 2000, 275: 36590-36595.
83. Sipols A.J., Baskin D.G., Schwartz M.W. Effect of intracerebroventricular insulin infusion on diabetic hyperphagia and hypothalamic neuropeptide gene expression. Diabetes 1995, 44: 147-151.
84. Pi-Sunyer FX. Guidelines for the approval and use of drugs to treat obesity - A position paper for the study of obesity. Obes. Res. 1995, 3: 473-478.